Bausch + Lomb (BLCO) Q1 2026: 59% EBITDA Growth Reflects Operating Leverage and Pipeline Momentum
Bausch + Lomb demonstrated robust operational execution with significant adjusted EBITDA growth driven by sustained revenue momentum and margin expansion. The company’s diversified portfolio and strategic investments in innovation underpin confidence in meeting ambitious multi-year financial targets. Guidance was raised, reflecting strong start to 2026 and expectations for continued operating leverage.
Summary
- Margin Expansion Catalyzed by Structural Changes: Operational discipline and Vision 27 initiative drove over 300 basis points SG&A margin improvement.
- Pharmaceutical and Premium Products Lead Growth: Double-digit revenue growth in dry eye pharmaceuticals and premium intraocular lenses signals durable demand.
- Pipeline Progress and AI Integration: Active R&D milestones and AI adoption enhance innovation and operational efficiency.
Business Overview
Bausch + Lomb is a leading global eye health company that generates revenue through three major segments: Vision Care, Surgical, and Pharmaceuticals. The Vision Care segment includes consumer products and contact lenses, Surgical covers premium intraocular lenses (IOLs) and related equipment, while Pharmaceuticals focuses on prescription medicines primarily for dry eye and ocular surface diseases. The company leverages a diversified portfolio to address multiple facets of eye health worldwide.
Performance Analysis
Bausch + Lomb reported total revenue of $1.244 billion for Q1 2026, marking a 6% increase on a constant currency basis compared to Q1 2025. This growth was broad-based, with Pharmaceuticals leading at 12% constant currency growth, Vision Care up 5%, and Surgical growing 1%. The Pharmaceuticals segment’s strong performance was driven by MIEBO® and XIIDRA®, which grew 33% and 30% respectively, reflecting successful commercialization and market penetration.
Adjusted EBITDA excluding acquired in-process research and development (IPR&D) surged 59% year-over-year to $200 million, with margin expansion of 500 basis points to 16.1%. This surge reflects the company’s effective cost discipline under its Vision 27 initiative, improving SG&A efficiency by over 300 basis points, and operational leverage from a favorable product mix shift toward higher-margin offerings such as dry eye products and premium IOLs.
- Segment Growth Drivers: Vision Care growth was supported by a 25% increase in daily silicone hydrogel (SiHy) contact lenses and a 16% rise in consumer dry eye products.
- Operational Leverage Realized: Margin expansion was underpinned by streamlined indirect support, productivity initiatives in manufacturing and supply chain, and disciplined expense management.
- Cash Flow and Capital Allocation: Operating cash flow turned positive at $32 million, improving $57 million year-over-year, while capital expenditures remained front-loaded at $100 million for the quarter.
Overall, the quarter demonstrates that Bausch + Lomb’s foundational restructuring and strategic focus on premiumization and innovation are translating into tangible financial gains, setting the stage for sustainable growth and margin improvement.
Executive Commentary
"We’re doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward."
Brent Saunders, Chairman and Chief Executive Officer
"We delivered meaningful operating leverage with adjusted EBITDA reported growth of 59% on a year-over-year basis. The performance highlights the structural changes we have made to drive operating leverage, which are now translating into P&L flow-through."
Sam Aldasuki, Chief Financial Officer
Strategic Positioning
1. Accelerating Premiumization Across Segments
Bausch + Lomb is strategically shifting its portfolio mix toward higher-margin premium products. The Surgical segment’s premium intraocular lenses grew 27% on a constant currency basis, with the Envy trifocal lens up 88%, signaling strong surgeon adoption and patient demand. The company’s expansion of premium IOLs in Europe with the launch of Invista Envy and upgrades to preloaded systems further reinforce this trajectory.
2. Leadership in Dry Eye Pharmaceuticals
Pharmaceuticals continue to be a growth engine, driven by MIEBO and XIIDRA, which together anchor the company’s dry eye portfolio. The transition from launch to growth phase is evident in the 33% and 30% revenue growth respectively, supported by increased prescriber familiarity and market expansion despite competitive pressures. The strategic withdrawal from the CVS contract for XIIDRA improved revenue quality and profitability.
3. Consumer Business Expansion and Innovation
The consumer segment remains a durable contributor, led by strong brands such as Lumify, Blink, and PreserVision. The launch of PreserVision AREDS3™ with a novel B vitamin complex expands the addressable market significantly, targeting early-stage age-related macular degeneration patients. The company’s focus on professional endorsement and education aims to accelerate adoption over multiple years.
4. Operational Excellence Fueled by AI and Productivity Initiatives
Bausch + Lomb is embedding artificial intelligence across commercial and operational functions, enhancing sales effectiveness, customer targeting, and supply chain efficiency. These investments support the Vision 27 initiative’s goal of improving financial discipline and operational agility, which is reflected in the 340 basis points SG&A margin improvement and improved cash flow generation.
5. Field Force Rebuild and Commercial Execution
The company undertook a deliberate rebuild of its U.S. surgical field force to better align with its expanding premium portfolio and upcoming product launches such as Elios. Early signs show rising productivity and improved sales trends, which are expected to drive sequential improvement in the surgical segment throughout 2026.
Key Considerations
Bausch + Lomb’s Q1 performance confirms that disciplined execution and portfolio premiumization are driving operating leverage and margin expansion.
- Seasonality in Pharmaceuticals: The dry eye market exhibits strong seasonality with Q1 as the weakest quarter; the company’s strong growth despite this bodes well for the remainder of the year.
- Geographic Market Dynamics: Contact lens growth was stronger in the U.S. where the full portfolio is available; international markets, especially Asia, show softness due to economic factors but remain strategic priorities.
- Pipeline Visibility: Ongoing R&D milestones, including the NDA filing for Lumify Next and CE mark submissions, provide tangible catalysts for future growth.
- Capital Allocation Focus: Front-loaded CapEx supports manufacturing and supply chain improvements, with expectations for lighter spending in the second half of the year.
- Leverage Reduction Commitment: The company aims to reduce net leverage to 3.5 times by 2028, supported by strong EBITDA growth and cash flow generation.
Risks
Potential risks include geopolitical uncertainties impacting logistics and costs, particularly elevated oil prices, which could pressure margins. The company also faces competitive pressures in pharmaceuticals and contact lenses, and reimbursement challenges in surgical markets. Seasonality and macroeconomic softness in key international markets could temper near-term growth. Execution risks remain in the surgical field force rebuild and new product launches.
Forward Outlook
For Q2 2026, Bausch + Lomb anticipates:
- Revenue growth consistent with a 25% contribution toward full-year midpoint guidance.
- Adjusted EBITDA margin expansion with approximately 22.5% of full-year EBITDA expected.
Management raised full-year 2026 guidance to $5.42 billion to $5.52 billion in revenue, representing 5.3% to 7.2% constant currency growth, and adjusted EBITDA excluding acquired IPR&D to $1.01 billion to $1.06 billion. The company expects adjusted gross margin of approximately 62%, R&D investment of 7.5% to 8% of revenue, and interest expense near $365 million. CapEx guidance remains at $285 million, weighted toward the first half of the year.
Takeaways
Bausch + Lomb’s Q1 results underscore the company’s successful execution of a multi-year transformation focused on premiumization, operational discipline, and innovation.
- Financial Leverage Realized: The 59% adjusted EBITDA growth and 500 basis points margin expansion illustrate that strategic cost initiatives and portfolio shifts are delivering sustainable earnings quality.
- Growth Engine Diversity: Strong performances across pharmaceuticals, vision care, and surgical segments reduce reliance on any single market and position the company for resilient growth.
- Pipeline and AI as Differentiators: Continued R&D progress and AI integration offer competitive advantages that should support long-term growth and margin expansion beyond 2026.
Conclusion
Bausch + Lomb’s first quarter 2026 results reflect disciplined execution and strategic clarity, with strong revenue growth, margin expansion, and pipeline advancement. The raised guidance and positive momentum across segments provide a solid foundation for achieving the company’s multi-year financial targets and delivering sustained shareholder value.
Industry Read-Through
Bausch + Lomb’s performance highlights broader industry trends of premiumization in eye care, the growing importance of integrated prescription and OTC dry eye solutions, and the operational benefits of AI adoption. The company’s emphasis on pipeline visibility and commercial execution serves as a benchmark for peers navigating competitive and reimbursement challenges. Investors and industry participants should watch how surgical field force realignments and product innovations shape market share dynamics in premium IOLs and equipment.